Your Search for 'AstraZeneca: Performance, Products, Pipeline and Potential' returned 115 results - Page 1 of 6

• AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Mar 2013 , Pages: 64
  Employees AstraZeneca PLC, Key Employee Biographies AstraZeneca PLC, Major Products and Services AstraZeneca PLC, Number of Pipeline Products by Therapy Area AstraZeneca PLC, Number of Pipeline ...

• AstraZeneca PLC Market Share Analysis

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jun 2011 , Pages: 110
  Financial Performance 4.4 SWOT Snapshot 4.5 Business Overview 4.6 Major Products and Services 4.6.1 Overview 5 History 6 SWOT Analysis 6.1 Overview 6.2 AstraZeneca PLC Strengths 6.2.1 Widespread ...

• The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016

  EURO€ 2,948.00USD$ 3,835.00GBP£ 2,480.00AUD$ 3,751.00JPY¥ 378,641.00SEK 25 180,00CHF 3'615.00CAD$ 3,908.00 Scripp Business Insights, May 2011 , Pages: 81
  major indications, and evaluate the market share of these companies. - Gain comprehensive understanding of how recent events are affecting the performance of major products and companies. - Forecast ...

• Inhaled Pain Management: Products, Therapeutics, Markets and Forecasts

  EURO€ 2,191.00USD$ 2,850.00GBP£ 1,843.00AUD$ 2,788.00JPY¥ 281,389.00SEK 18 713,00CHF 2'686.00CAD$ 2,904.00 Greystone Associates, May 2011
  markets. Highlights - Analyzes and evaluates intranasal and orally inhaled pain management products and pipeline candidates and assesses the market potential for existing and probable future products ...

• BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

  EURO€ 2,000.00USD$ 2,602.00GBP£ 1,683.00AUD$ 2,545.00JPY¥ 256,897.00SEK 17 084,00CHF 2'452.00CAD$ 2,651.00 Kelly Scientific Publications, May 2013 , Pages: 105
  : Important Milestones in AstraZeneca China's History Table 7.19: AstraZeneca China Anaesthetic Range of Products Table 7.20: AstraZeneca China Cardiovascular and Metabolism Range of Products Table 7.21 ...

• The Cancer Market Outlook to 2016

  EURO€ 2,948.00USD$ 3,835.00GBP£ 2,480.00AUD$ 3,751.00JPY¥ 378,641.00SEK 25 180,00CHF 3'615.00CAD$ 3,908.00 Scripp Business Insights, Jun 2011 , Pages: 164
  analysis AstraZeneca Sales focus by drug class Regional sales distribution Leading products Pipeline analysis Strategic and growth analysis Sanofi Sales focus by drug class Regional sales ...

• Global Biopharma Outlook 2012 - Major US and EU Pharma

  EURO€ 2,306.00USD$ 3,000.00GBP£ 1,940.00AUD$ 2,934.00JPY¥ 296,199.00SEK 19 698,00CHF 2'828.00CAD$ 3,057.00 MP Advisors, Jan 2012 , Pages: 109
  intended for the generic pharmaceutical companies, and small to mid cap research focused companies as it will help them identify product opportunities and potential partners. Company Analyses: AstraZeneca ...

• Astra Tech AB - Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Aug 2011 , Pages: 25
  . Astra Tech operates through 16 subsidiaries and a network of distributors across the world to market its products. The company is a subsidiary of AstraZeneca Plc, and is headquartered in Molndal, Sweden ...

• Lung Cancer Therapeutics Market Outlook and Pipeline Analysis

  EURO€ 1,918.00USD$ 2,495.00GBP£ 1,613.00AUD$ 2,440.00JPY¥ 246,339.00SEK 16 382,00CHF 2'352.00CAD$ 2,542.00 Arrowhead Publishers, Nov 2009
  maximize your product’s commercial potential - Gain an impartial perspective of the strategies used between competing companies involved in the lung cancer pipeline to enhance your product’s performance 1 ...

• Global Biopharma Outlook 2011: Major US and EU

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 MP Advisors, Feb 2011 , Pages: 90
  generic exposure analysis and sales projections to 2015. Global Pharma: Macro View 2010 Performance - 2010 - A Year of Underperformance for the Sector - Our View on the potential of Major NME/BLA ...

• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013

  EURO€ 455.00USD$ 425.00GBP£ 258.00AUD$ 619.00JPY¥ 52,150.00SEK 3 667,00CHF 610.00CAD$ 568.00 Cambridge Healthtech Institute, Jun 2012
  U.S. Pharma: NPV of New Launches and Pipeline Products as Proportion of Marketed Products U.S. Pharma: Peak Sales of New Launches and Pipeline Candidates as Proportions of 2010e Sales European Pharmas ...

• The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

  EURO€ 1,345.00USD$ 1,750.00GBP£ 1,132.00AUD$ 1,712.00JPY¥ 172,783.00SEK 11 490,00CHF 1'649.00CAD$ 1,783.00 Arrowhead Publishers, Oct 2010 , Pages: 385
  in Postoperative Pain 4.3.5 Multi-Modal Analgesia Used in Postoperative Pain 4.4 Leading Brand Products in the Postoperative Pain Market 4.4.1 AstraZeneca/Abraxis BioScience's Naropin (ropivacaine ...

• DPP IV Inhibitors - Global Strategic Business Report

  EURO€ 3,717.00USD$ 4,200.00GBP£ 2,478.00AUD$ 5,808.00JPY¥ 503,659.00SEK 33 040,00CHF 5'531.00CAD$ 5,387.00 Global Industry Analysts, Inc, Sep 2011 , Pages: 363
  . Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc ...

• Top 50 Pharmaceutical Companies & Their Pipelines 2011

  EURO€ 373.00USD$ 485.00GBP£ 314.00AUD$ 474.00JPY¥ 47,885.00SEK 3 184,00CHF 457.00CAD$ 494.00 UBM Canon, Sep 2011 , Pages: 234
  U.S. and EU as well as FDA approval for generic Enoxaparin. The Swiss company has at least seven more potential blockbusters in the pipeline. The following information is included for the top 50 ...

• The CNS Market Outlook to 2010

  EURO€ 2,210.00USD$ 2,875.00GBP£ 1,859.00AUD$ 2,812.00JPY¥ 283,857.00SEK 18 877,00CHF 2'710.00CAD$ 2,930.00 Scripp Business Insights, Oct 2005
  ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth. This report will enable you to benchmark the strategies behind the market-leading products of today and ...

• Personalized Medicine 2010

  EURO€ 1,149.00USD$ 1,495.00GBP£ 967.00AUD$ 1,462.00JPY¥ 147,606.00SEK 9 816,00CHF 1'409.00CAD$ 1,523.00 Arrowhead Publishers, May 2010 , Pages: 261
  Articulate the benefits of products in the pipeline to payers and regulators as early as possible in the R&D process to win their support and avoid the time and expense of developing a drug or diagnostic that ...

• The Cancer Market Outlook to 2010

  EURO€ 2,210.00USD$ 2,875.00GBP£ 1,859.00AUD$ 2,812.00JPY¥ 283,857.00SEK 18 877,00CHF 2'710.00CAD$ 2,930.00 Scripp Business Insights, Nov 2005
  analysis and market share of the top players in the cancer market including: - Roche, Johnson & Johnson, AstraZeneca, Novartis, BMS and Sanofi-Aventis - Epidemiological analysis and forecasts in 9 key ...

• Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GlobalData, Oct 2011 , Pages: 95
  , Pipeline Products, 2011 Table 37: Novartis, Depression Pipeline, 2011 Table 38: AstraZeneca PLC, Depression Pipeline, 2011 Table 39: Eli Lilly and Company, Depression Pipeline, 2011 Table 40: Targacept ...

• Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Jan 2012 , Pages: 69
  and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business ...

• Global Biopharma Outlook 2011

  EURO€ 5,381.00USD$ 7,000.00GBP£ 4,527.00AUD$ 6,847.00JPY¥ 691,131.00SEK 45 961,00CHF 6'598.00CAD$ 7,133.00 MP Advisors, Jan 2011 , Pages: 391
  - Du Pont Analyses of Indian Companies - FIIs Holdings - Change in Shareholding - NCE and Biologic pipeline of Indian Companies Global Pharma: Macro View 2010 Performance - 2010 - A Year of ...